All Eyes On Amjevita, Amgen’s Humira Biosimilar And Sole 2023 Product Launch
Dual Pricing Strategy Addresses Unique US Payer Priorities
Executive Summary
The company launched Amjevita on the same day it announced fourth quarter 2022 earnings and provided 2023 guidance, upping the high-profile nature of the first-to-market US Humira biosimilar.
You may also be interested in...
CVS Launches Cordavis To Make US Biosimilars More Accessible, Affordable
CVS Health’s new subsidiary Cordavis will help manufacturers produce and/or commercialize biosimilars with the aim of reducing overall drug costs while improving access to and affordability of medicines.
AbbVie Wary Of IRA Potential Impact On Struggling Imbruvica
While AbbVie tries to estimate which of its products might fall into CMS price negotiations, it is seeing lower-than-expected sales erosion for Humira and continued growth for Skyrizi and Rinvoq.
History Repeats: Will US Stelara Settlements Follow Humira’s Lead?
Hopes are rising that Johnson & Johnson will be able to emulate AbbVie’s success in delaying US biosimilar competition to its top-selling Humira by using a similar settlement strategy with its anti-IL12/IL23 blockbuster Stelara.